Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, double-blind, randomised, placebo-controlled phase II trial with a 3 week treatment period to assess the efficacy, safety and tolerability of add-on treatment with Ketamine hydrochloride prolonged release tablets (KET01, 120 mg or 240 mg once daily) in outpatients with treatment resistant depression

Next Previous
X
Search
Trial Profile

A multicentre, double-blind, randomised, placebo-controlled phase II trial with a 3 week treatment period to assess the efficacy, safety and tolerability of add-on treatment with Ketamine hydrochloride prolonged release tablets (KET01, 120 mg or 240 mg once daily) in outpatients with treatment resistant depression

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketamine (Primary) ; Antidepressants
  • Indications Depression
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Ketabon

    • Most Recent Events

    • 18 Sep 2024 According to Ketabon Media Release, Combined Results from KET01-02 and KET01-03 Trials will be presented as posters at the 37th European College of Neuropsychopharmacology (ECNP) Congress 2024, taking place on September 21-24, 2024 in Milan.
    • 21 May 2024 According to Ketabon GmbH media release, the Company will present poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place on May 28-31, 2024 at Miami Beach.
    • 13 Nov 2023 According to Ketabon GmbH media release, In-Depth data from this trial has been presented at CNS Summit in Boston.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top